Melvin Spigelman

6.4k total citations · 4 hit papers
43 papers, 3.8k citations indexed

About

Melvin Spigelman is a scholar working on Infectious Diseases, Epidemiology and Oncology. According to data from OpenAlex, Melvin Spigelman has authored 43 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Infectious Diseases, 16 papers in Epidemiology and 9 papers in Oncology. Recurrent topics in Melvin Spigelman's work include Tuberculosis Research and Epidemiology (22 papers), Mycobacterium research and diagnosis (7 papers) and Pneumocystis jirovecii pneumonia detection and treatment (6 papers). Melvin Spigelman is often cited by papers focused on Tuberculosis Research and Epidemiology (22 papers), Mycobacterium research and diagnosis (7 papers) and Pneumocystis jirovecii pneumonia detection and treatment (6 papers). Melvin Spigelman collaborates with scholars based in United States, United Kingdom and South Africa. Melvin Spigelman's co-authors include Ann M. Ginsberg, Carl M. Mendel, Christo van Niekerk, Daniel E. Everitt, Keertan Dheda, Mario Raviǵlione, Marcel A. Behr, Haileyesus Getahun, David W. Dowdy and Maziar Divangahi and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Nature Medicine.

In The Last Decade

Melvin Spigelman

42 papers receiving 3.7k citations

Hit Papers

Tuberculosis 2016 2026 2019 2022 2016 2020 2022 2022 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Tuberculosis
    2016 814 citations Madhukar Pai, Marcel A. Behr et al. Nature Reviews Disease Primers profile →
  2. Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
    2020 585 citations Francesca Conradie, Andreas H. Diacon et al. profile →
  3. Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed.
    2022 167 citations Mark S. Butler, Valeria Gigante et al. Oxford University Research Archive (ORA) (University of Oxford) profile →
  4. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis
    2022 154 citations Mohammed Rassool, Timothy D. McHugh et al. profile →

Peers

Melvin Spigelman
Sandeep Tyagi United States
Anne J. Lenaerts United States
Wing Wai Yew China
Petros C. Karakousis United States
Michael H. Cynamon United States
C. Truffot-Pernot France
Khisimuzi Mdluli United States
Rodney Dawson South Africa
Ken Duncan United Kingdom
Anil Koul Belgium
Sandeep Tyagi United States
Melvin Spigelman
Citations per year, relative to Melvin Spigelman Melvin Spigelman (= 1×) peers Sandeep Tyagi

Countries citing papers authored by Melvin Spigelman

Since Specialization
Citations

This map shows the geographic impact of Melvin Spigelman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Melvin Spigelman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Melvin Spigelman more than expected).

Fields of papers citing papers by Melvin Spigelman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Melvin Spigelman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Melvin Spigelman. The network helps show where Melvin Spigelman may publish in the future.

Co-authorship network of co-authors of Melvin Spigelman

This figure shows the co-authorship network connecting the top 25 collaborators of Melvin Spigelman. A scholar is included among the top collaborators of Melvin Spigelman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Melvin Spigelman. Melvin Spigelman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Butler, Mark S., Valeria Gigante, Hatim Sati, et al.. (2022). Analysis of the clinical pipeline of treatments for drug resistant bacterial infections: despite progress, more action is needed.. Oxford University Research Archive (ORA) (University of Oxford). 167 indexed citations breakdown →
2.
Gomez, Gabriela B., Mariana Siapka, Francesca Conradie, et al.. (2021). Cost-effectiveness of bedaquiline, pretomanid and linezolid for treatment of extensively drug-resistant tuberculosis in South Africa, Georgia and the Philippines. BMJ Open. 11(12). e051521–e051521. 18 indexed citations
3.
Tweed, Conor, Angela M. Crook, Rodney Dawson, et al.. (2019). Toxicity related to standard TB therapy for pulmonary tuberculosis and treatment outcomes in the REMoxTB study according to HIV status. BMC Pulmonary Medicine. 19(1). 152–152.
4.
5.
Theuretzbacher, Ursula, Peter Beyer, Mark S. Butler, et al.. (2018). Analysis of the clinical antibacterial and antituberculosis pipeline. The Lancet Infectious Diseases. 19(2). e40–e50. 159 indexed citations
6.
Tweed, Conor, Genevieve H. Wills, Angela M. Crook, et al.. (2018). Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Medicine. 16(1). 46–46. 50 indexed citations
7.
Tweed, Conor, Angela M. Crook, Evans Amukoye, et al.. (2018). Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Infectious Diseases. 18(1). 317–317. 27 indexed citations
8.
Murphy, Michael E., Genevieve H. Wills, Robert D. Hunt, et al.. (2018). Gender differences in tuberculosis treatment outcomes: a post hoc analysis of the REMoxTB study. BMC Medicine. 16(1). 189–189. 28 indexed citations
9.
Pai, Madhukar, Marcel A. Behr, David W. Dowdy, et al.. (2016). Tuberculosis. Nature Reviews Disease Primers. 2(1). 16076–16076. 814 indexed citations breakdown →
10.
11.
Diacon, Andreas H., Rodney Dawson, Florian von Groote-Bidlingmaier, et al.. (2012). 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. The Lancet. 380(9846). 986–993. 328 indexed citations
12.
So, Anthony D., Samir K. Brahmachari, I. Chopra, et al.. (2011). Towards new business models for R&D for novel antibiotics. Drug Resistance Updates. 14(2). 88–94. 49 indexed citations
13.
Nuermberger, Eric, Melvin Spigelman, & Wing Wai Yew. (2010). Current development and future prospects in chemotherapy of tuberculosis. Respirology. 15(5). 764–778. 53 indexed citations
14.
Spigelman, Melvin. (2007). New Tuberculosis Therapeutics: A Growing Pipeline. The Journal of Infectious Diseases. 196(s1). S28–S34. 131 indexed citations
15.
Ginsberg, Ann M. & Melvin Spigelman. (2007). Challenges in tuberculosis drug research and development. Nature Medicine. 13(3). 290–294. 219 indexed citations
16.
Spigelman, Melvin & Stephen H. Gillespie. (2006). Tuberculosis drug development pipeline: progress and hope. The Lancet. 367(9514). 945–947. 40 indexed citations
17.
Kreis, Willi, Keith K. H. Chan, Daniel R. Budman, et al.. (1996). Clinical Pharmacokinetics of Amonafide (NSC 308847) in 62 Patients. Cancer Investigation. 14(4). 320–327. 4 indexed citations
18.
Spigelman, Melvin, Marco Chinol, Rosario A. Zappulla, et al.. (1993). Effect of Blood-Brain Barrier and Blood-Tumor Barrier Modification on Central Nervous System Liposomal Uptake. Cancer Investigation. 11(2). 118–128. 23 indexed citations
19.
Zappulla, Rosario A., et al.. (1986). The protective effect of experimental subarachnoid haemorrhage on sodium dehydrocholate-induced blood-brain barrier disruption. Acta Neurochirurgica. 83(3-4). 138–143. 9 indexed citations
20.
Spigelman, Melvin, Rosario A. Zappulla, Judith D. Goldberg, et al.. (1984). Effect of Intracarotid Etoposide on Opening the Blood-Brain Barrier. 1(3). 207–211. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Sandeep Tyagi Breakdown of academic impact, for papers by Anne J. Lenaerts Breakdown of academic impact, for papers by Wing Wai Yew Breakdown of academic impact, for papers by Petros C. Karakousis Breakdown of academic impact, for papers by Michael H. Cynamon Breakdown of academic impact, for papers by C. Truffot-Pernot Breakdown of academic impact, for papers by Khisimuzi Mdluli Breakdown of academic impact, for papers by Rodney Dawson Breakdown of academic impact, for papers by Ken Duncan Breakdown of academic impact, for papers by Anil Koul
Rankless by CCL
2026